ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TCRT vs UPC // OPERATING MARGIN

Alaunos Therapeutics Inc. (NASDAQ) VS. Universe Pharmaceuticals Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: TCRT 3 — UPC 3
▲ OPERATING MARGIN LEADER: UPC
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TCRT VS. UPC) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TCRT UPC SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 35.30% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin ACTIVE -60.00% -16.30% -43.70 UPC /operating-margins <GO>
Net Profit Margin -60.00% -20.60% -39.40 UPC /net-margins <GO>
Revenue Growth (YoY) -50.00% -22.40% -27.60 UPC /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 TCRT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 50.0 22.2 +27.79 TCRT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $7.8M $7.7M $65.2K TCRT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TCRT REV UPC REV TCRT GROSS % UPC GROSS % TCRT FCF UPC FCF
FY 2025 $5.0K $17.86B — 35.3% -$3.0M -$5.32B
FY 2024 $10.0K $23.02B — 26.4% -$5.0M -$9.72B
FY 2023 $5.0K $32.31B — — -$30.1M $1.12B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TCRT // BETA —
UPC // BETA —